CLAIRVO TECHNOLOGIES, Inc. (hereinafter, 'Clairvo'), a wholly owned subsidiary of Marubeni Corporation, has obtained market authorization for VIDA Insights, an image analysis software to assist in the reading of chest CT images developed by VIDA Diagnostics Inc. in accordance with the Pharmaceutical and Medical Device Act ('PMD Act').

The product is Clairvo's first certified under the PMD Act; Clairvo has begun marketing and selling the product since April 2022.

Medical imaging, such as X-ray and CT images, is used by medical institutions for diagnosis of diseases, determination of treatment plans, and follow-up after surgery. In recent years, the number of medical images taken has been increasing rapidly due to the growing health consciousness of people and technological innovations in imaging equipment, and the burden on physicians who give diagnoses has also been increasing.

The Product empowers physicians with quantitative data and impactful visualizations aimed to raise quality of care. For example, it provides care teams with low, high, and normal values for tissue density 1 in each lung lobe from chest CT images and provides easy-to-understand information on the entire lung visually using proprietary technology. It is certified as a medical device in the US, EU, Canada, and Australia where it has been accepted into clinical workflow by major medical institutions

Through Clairvo, Marubeni will contribute to solving issues in Japanese healthcare by providing superior products that support medical institutions.

(C) 2022 Electronic News Publishing, source ENP Newswire